Araujo, D.V.; Muniz, T.P.; Yang, A.; Keshavarzi, S.; Sorotsky, H.; Butler, M.O.; Saibil, S.; Spreafico, A.; Hogg, D.
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Curr. Oncol. 2021, 28, 2173-2179.
https://doi.org/10.3390/curroncol28030201
AMA Style
Araujo DV, Muniz TP, Yang A, Keshavarzi S, Sorotsky H, Butler MO, Saibil S, Spreafico A, Hogg D.
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Current Oncology. 2021; 28(3):2173-2179.
https://doi.org/10.3390/curroncol28030201
Chicago/Turabian Style
Araujo, Daniel V., Thiago Pimentel Muniz, Anjie Yang, Sareh Keshavarzi, Hadas Sorotsky, Marcus O. Butler, Samuel Saibil, Anna Spreafico, and David Hogg.
2021. "Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events" Current Oncology 28, no. 3: 2173-2179.
https://doi.org/10.3390/curroncol28030201
APA Style
Araujo, D. V., Muniz, T. P., Yang, A., Keshavarzi, S., Sorotsky, H., Butler, M. O., Saibil, S., Spreafico, A., & Hogg, D.
(2021). Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Current Oncology, 28(3), 2173-2179.
https://doi.org/10.3390/curroncol28030201
